March 21st 2023
Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.
Guselkumab Shows Long-Term Improvement in Quality of Life for Patients With Active Psoriatic ArthritisNovember 16th 2022
Guselkumab (Tremfya) is a fully human selective IL-23 inhibitor therapy FDA-approved for the treatment of adults with active psoriatic arthritis and with moderate to severe plaque psoriasis.
Holistic Psoriatic Arthritis Care: Why Well-Being Should Be Incorporated Into the Treatment ParadigmJuly 25th 2022
People living with psoriatic arthritis deserve to be informed about ways to approach disease management holistically and with a personalized approach.
FDA Approves Abatacept With Calcineurin Inhibitor for Prophylaxis of Acute Graft Versus Host DiseaseDecember 17th 2021
Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.
Upadacitinib Receives FDA Approval for Treatment of Active Psoriatic ArthritisDecember 15th 2021
The safety profile observed in patients with active psoriatic arthritis administered upadacitinib was consistent with the safety profile observed in patients with rheumatoid arthritis.
High Risk of Bias Associated With Studies of COVID-19 Risk in Patients with Psoriasis, Psoriatic ArthritisAugust 20th 2021
The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.
Pharmacist Medication Insights: Risankizumab-rzaa for Moderate-to-Severe Plaque PsoriasisJune 10th 2021
Risankizumab-rzaa (Skyrizi, AbbVie) is approved for the treatment of moderate-to-severe plaque psoriasis among adults who are candidates for systemic therapy or phototherapy.
Data Show Durable, Complete Plaque Psoriasis Skin Clearance Through 5 Years With GuselkumabJune 7th 2021
Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.
Deucravacitinib Shown More Effective Than Apremilast in Treating Moderate to Severe Plaque Psoriasis in Phase 3 TrialsApril 23rd 2021
The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.
Secukinumab has Early and Sustained Efficacy on Enthesitis in Patients with Psoriatic ArthritisJanuary 9th 2020
Secukinumab provided early and sustained resolution of enthesitis in patients with psoriatic arthritis based on post hoc analysis pooled data from the FUTURE trial.
Psoriasis Patients Without Psoriatic Arthritis Benefit More From MethotrexateFebruary 4th 2019
A study of methotrexate in patients with psoriasis found that the immunosuppressive drug was more effective in patients without psoriatic arthritis than those with the added condition.
Updated Secukinumab Label to Include Evidence for Treatment of Psoriatic ArthritisJune 20th 2018
The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.